Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rusch, V. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rusch, V. W.
(Chest. 1994;106:408S-410S.)
© 1994 American College of Chest Physicians

Should We Reestablish the Lung Cancer Study Group?

Valerie W. Rusch MD, FCCP1

1 From the Thoracic Surgery Service, Memorial Sloan-Kettering Cancer Center, New York

The hallmark of the Lung Cancer Study Group (LCSG) was its multidisciplinary approach to cancer management, based on close collaboration among thoracic surgeons, medical oncologists, radiation oncologists, pathologists, biostatisticians, and data managers. Discontinuation of funding for the group dispersed a critical mass of thoracic oncologists and had serious adverse effects on clinical trials in early-stage thoracic malignancies, on translational research, and on oncologic education. The use of an intergroup mechanism for clinical trials has been partially successful in continuing the work started by the LCSG, but a sustained effort will be necessary to recreate the framework for clinical investigation provided by the group.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American College of Chest Physicians.